Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 42
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records

  • Perera, Gayan
  • Rijnbeek, Peter
  • Alexander, Myriam
  • Ansel, David
  • Avillach, Paul
  • Duarte Salles, Talita, 1985-
  • Gordon, Mark F.
  • Lapi, Francesco
  • Mayer, Miguel Ángel, 1960-
  • Pasqua, Alessandro
  • Pedersen, Lars
  • van der Lei, Johan
  • Visser, Pieter Jelle
  • Stewart, Robert
Objective: The objective of the study is to compare body mass index (BMI), systolic/diastolic blood pressure (SBP/DBP) and serum total cholesterol levels between dementia cases and controls at multiple time intervals prior to dementia onset, and to test time interval as a modifying factor for these associations. Design: Case-control study. Setting: Six European electronic health records databases. Participants: 291 780 cases at the date of first-recorded dementia diagnosis, compared with 29 170 549 controls randomly selected from the same databases, age matched and sex matched at this index date. Exposure: The following measures were extracted whenever recorded within each dataset: BMI (kg/m2), SBP and DBP (mm Hg) and serum total cholesterol (mmol/L). Levels for each of these variables were defined within six 2-year time intervals over the 12 years prior to the index date. Main outcomes: Case-control differences in exposures of interest were modelled for each time period and adjusted for demographic and clinical factors (ischaemic/unspecified stroke, type 2 diabetes mellitus, acute myocardial infarction, hypertension diagnosis, antihypertensive medication, cholesterol-lowering medication). Coefficients and interactions with time period were meta-analysed across the six databases. Results: Mean BMI (coefficient -1.16 kg/m2; 95% CI -1.38 to 0.93) and SBP (-2.83 mm Hg; 95% CI -4.49 to -1.16) were lower in cases at diagnosis, and case-control differences were greater in more recent time periods, as indicated by significant case-x-time interaction and case-x-time-squared interaction terms. Time variations in coefficients for cholesterol levels were less consistent between databases and those for DBP were largely not significant. Conclusion: Routine clinical data show emerging divergence in levels of BMI and SBP prior to the diagnosis of dementia but less evidence for DBP or total cholesterol levels. These divergences should receive at least some consideration in routine dementia risk screening, although underlying mechanisms still require further investigation., The research leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under EMIF grant agreement n° 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. RS and GP are part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project.

  • Roberto, Giuseppe
  • Mayer, Miguel Ángel, 1960-
  • Gini, Rosa
Due to the heterogeneity of existing European sources of observational healthcare data, data source-tailored choices are needed to execute multi-data source, multi-national epidemiological studies. This makes transparent documentation paramount. In this proof-of-concept study, a novel standard data derivation procedure was tested in a set of heterogeneous data sources. Identification of subjects with type 2 diabetes (T2DM) was the test case. We included three primary care data sources (PCDs), three record linkage of administrative and/or registry data sources (RLDs), one hospital and one biobank. Overall, data from 12 million subjects from six European countries were extracted. Based on a shared event definition, sixteeen standard algorithms (components) useful to identify T2DM cases were generated through a top-down/bottom-up iterative approach. Each component was based on one single data domain among diagnoses, drugs, diagnostic test utilization and laboratory results. Diagnoses-based components were subclassified considering the healthcare setting (primary, secondary, inpatient care). The Unified Medical Language System was used for semantic harmonization within data domains. Individual components were extracted and proportion of population identified was compared across data sources. Drug-based components performed similarly in RLDs and PCDs, unlike diagnoses-based components. Using components as building blocks, logical combinations with AND, OR, AND NOT were tested and local experts recommended their preferred data source-tailored combination. The population identified per data sources by resulting algorithms varied from 3.5% to 15.7%, however, age-specific results were fairly comparable. The impact of individual components was assessed: diagnoses-based components identified the majority of cases in PCDs (93-100%), while drug-based components were the main contributors in RLDs (81-100%). The proposed data derivation procedure allowed the generation of data source-tailored case-finding algorithms in a standardized fashion, facilitated transparent documentation of the process and benchmarking of data sources, and provided bases for interpretation of possible inter-data source inconsistency of findings in future studies., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking (http://www.imi.europa.eu/) under European Medical Information Framework grant agreement no. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Association companies’ in kind contribution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Pfizer Worldwide Research and Development, GlaxoSmithKline, Cegedim Strategic Data Medical Research Ltd and Janssen provided support in the form of salaries for AKL, PE, DA and MJS, respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Impact of cerebral blood flow and amyloid load on SUVR bias

  • Heeman, Fiona
  • Yaqub, Maqsood
  • Hendriks, Janine
  • van Berckel, Bart N. M.
  • Collij, Lyduine E.
  • Gray, Katherine R.
  • Manber, Richard
  • Wolz, Robin
  • Garibotto, Valentina
  • Wimberley, Catriona
  • Ritchie, Craig
  • Barkhof, Frederik
  • Gispert, Juan Domingo
  • Vállez García, David
  • Lopes Alves, Isadora
  • Lammertsma, Adriaan A.
  • AMYPAD Consortium
Background: despite its widespread use, the semi-quantitative standardized uptake value ratio (SUVR) may be biased compared with the distribution volume ratio (DVR). This bias may be partially explained by changes in cerebral blood flow (CBF) and is likely to be also dependent on the extent of the underlying amyloid-β (Aβ) burden. This study aimed to compare SUVR with DVR and to evaluate the effects of underlying Aβ burden and CBF on bias in SUVR in mainly cognitively unimpaired participants. Participants were scanned according to a dual-time window protocol, with either [18F]flutemetamol (N = 90) or [18F]florbetaben (N = 31). The validated basisfunction-based implementation of the two-step simplified reference tissue model was used to derive DVR and R1 parametric images, and SUVR was calculated from 90 to 110 min post-injection, all with the cerebellar grey matter as reference tissue. First, linear regression and Bland-Altman analyses were used to compare (regional) SUVR with DVR. Then, generalized linear models were applied to evaluate whether (bias in) SUVR relative to DVR could be explained by R1 for the global cortical average (GCA), precuneus, posterior cingulate, and orbitofrontal region. Results: despite high correlations (GCA: R2 ≥ 0.85), large overestimation and proportional bias of SUVR relative to DVR was observed. Negative associations were observed between both SUVR or SUVRbias and R1, albeit non-significant. Conclusion: the present findings demonstrate that bias in SUVR relative to DVR is strongly related to underlying Aβ burden. Furthermore, in a cohort consisting mainly of cognitively unimpaired individuals, the effect of relative CBF on bias in SUVR appears limited. EudraCT Number: 2018-002277-22, registered on: 25-06-2018., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this project received funding from the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking (EMIF grant:115372) and the EU-EFPIA IMI-2 Joint Undertaking (grant:115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. FB is supported by the NIHR biomedical research centre at UCLH. JDG holds a ‘Ramón y Cajal’ fellowship (RYC-2013-13054) from the Spanish Ministry of Science, Innovation and Universities. VG reports grants from the Swiss National Science Foundation (projects:320030_169876, 320030_185028 and IZSEZ0_188355) and the Velux foundation (project:1123).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Quality of hospital electronic health record (EHR) data based on the international consortium for health outcomes measurement (ICHOM) in heart failure: pilot data quality assessment study

  • Aerts, Hannelore
  • Kalra, Dipak
  • Sáez, Carlos
  • Ramírez Anguita, Juan Manuel
  • Mayer, Miguel Ángel, 1960-
  • García-Gómez, Juan M.
  • Durà-Hernández, Marta
  • Thienpont, Geert
  • Coorevits, Pascal
Background: There is increasing recognition that health care providers need to focus attention, and be judged against, the impact they have on the health outcomes experienced by patients. The measurement of health outcomes as a routine part of clinical documentation is probably the only scalable way of collecting outcomes evidence, since secondary data collection is expensive and error-prone. However, there is uncertainty about whether routinely collected clinical data within electronic health record (EHR) systems includes the data most relevant to measuring and comparing outcomes and if those items are collected to a good enough data quality to be relied upon for outcomes assessment, since several studies have pointed out significant issues regarding EHR data availability and quality. Objective: In this paper, we first describe a practical approach to data quality assessment of health outcomes, based on a literature review of existing frameworks for quality assessment of health data and multistakeholder consultation. Adopting this approach, we performed a pilot study on a subset of 21 International Consortium for Health Outcomes Measurement (ICHOM) outcomes data items from patients with congestive heart failure. Methods: All available registries compatible with the diagnosis of heart failure within an EHR data repository of a general hospital (142,345 visits and 12,503 patients) were extracted and mapped to the ICHOM format. We focused our pilot assessment on 5 commonly used data quality dimensions: completeness, correctness, consistency, uniqueness, and temporal stability. Results: We found high scores (>95%) for the consistency, completeness, and uniqueness dimensions. Temporal stability analyses showed some changes over time in the reported use of medication to treat heart failure, as well as in the recording of past medical conditions. Finally, the investigation of data correctness suggested several issues concerning the characterization of missing data values. Many of these issues appear to be introduced while mapping the IMASIS-2 relational database contents to the ICHOM format, as the latter requires a level of detail that is not explicitly available in the coded data of an EHR. Conclusions: Overall, results of this pilot study revealed good data quality for the subset of heart failure outcomes collected at the Hospital del Mar. Nevertheless, some important data errors were identified that were caused by fundamentally different data collection practices in routine clinical care versus research, for which the ICHOM standard set was originally developed. To truly examine to what extent hospitals today are able to routinely collect the evidence of their success in achieving good health outcomes, future research would benefit from performing more extensive data quality assessments, including all data items from the ICHOM standards set and across multiple hospitals., MAM and JMRA had support from the Innovative Medicines Initiative Joint Under-taking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies. The funders were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

  • Stamate, Daniel
  • Molinuevo, José Luis
  • Legido-Quigley, Cristina
Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers. This study analyzed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n = 883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV). On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively. This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disorders., The present study was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007–2013) and EFPIA companies’ in-kind contribution. The DESCRIPA study was funded by the European Commission within the fifth framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the fifth framework program (contract no. 37670). The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01. 41142.001.H). Kristel Sleegers is supported by the Research Fund of the University of Antwerp. Daniel Stamate is supported by the Alzheimer’s Research UK (ARUK-PRRF2017-012).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Federated discovery and sharing of genomic data using Beacons

  • Fiume, Marc
  • Rambla de Argila, Jordi
  • Torre, Sabela de la
  • Scollen, Serena
M.F. and S.O.M.D. are supported by Genome Quebec, Genome Canada, the Government of Canada, and the Ministère de l’Économie, Innovation et Exportation du Québec (Can-SHARE grant 141210); S.O.M.D. is supported by the Canadian Institutes of Health Research (grants EP1-120608; EP2-120609); M.H. is supported by BD2K NIH/NCI 5U54HG007990-02; S. Scollen, S.V., M.B., I.L., J.T., S.U.-R., S.d.l.T., M.L., H.S. and the EGA are supported by ELIXIR, the research infrastructure for life-science data. This work was supported by ELIXIR-EXCELERATE, funded by the European Commission within the Research Infrastructures programme of Horizon 2020, grant agreement number 676559 (J.D.S., I.L.), the Wellcome Trust grant numbers WT201535/Z/16/Z (P.F.) and WT098051 (S.K., D.L., P.F.). A.J.B. is supported by the European Union FP7 Programme ‘EMIF’ IMI-JU grant no. 115372, and H2020 Programme ‘GCOF’ grant no. 643439
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource

  • Perera, Gayan
  • Pedersen, Lars
  • Ansel, David
  • Alexander, Myriam
  • Arrighi, H. Michael
  • Avillach, Paul
  • Foskett, Nadia
  • Gini, Rosa
  • Gordon, Mark F.
  • Gungabissoona, Usha
  • Mayer, Miguel Ángel, 1960-
  • Novak, Gerald
  • Rijnbeek, Peter
  • Trifirò, Gianluca
  • van der Lei, Johan
  • Visser, Pieter Jelle
  • Stewart, Robert
INTRODUCTION: The European Medical Information Framework consortium has assembled electronic health record (EHR) databases for dementia research. We calculated dementia prevalence and incidence in 25 million persons from 2004 to 2012. METHODS: Six EHR databases (three primary care and three secondary care) from five countries were interrogated. Dementia was ascertained by consensus harmonization of clinical/diagnostic codes. Annual period prevalences and incidences by age and gender were calculated and meta-analyzed. RESULTS: The six databases contained 138,625 dementia cases. Age-specific prevalences were around 30% of published estimates from community samples and incidences were around 50%. Pooled prevalences had increased from 2004 to 2012 in all age groups but pooled incidences only after age 75 years. Associations with age and gender were stable over time. DISCUSSION: The European Medical Information Framework initiative supports EHR data on unprecedented number of people with dementia. Age-specific prevalences and incidences mirror estimates from community samples in pattern at levels that are lower but increasing over time., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under European Medical Informatics Framework (EMIF) grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind contribution. R.S. and G.P. are partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-based study

  • Giannoula, Alexia
  • Gutiérrez Sacristán, Alba
  • Bravo Serrano, Àlex, 1984-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Time is a crucial parameter in the assessment of comorbidities in population-based studies, as it permits to identify more complex disease patterns apart from the pairwise disease associations. So far, it has been, either, completely ignored or only, taken into account by assessing the temporal directionality of identified comorbidity pairs. In this work, a novel time-analysis framework is presented for large-scale comorbidity studies. The disease-history vectors of patients of a regional Spanish health dataset are represented as time sequences of ordered disease diagnoses. Statistically significant pairwise disease associations are identified and their temporal directionality is assessed. Subsequently, an unsupervised clustering algorithm, based on Dynamic Time Warping, is applied on the common disease trajectories in order to group them according to the temporal patterns that they share. The proposed methodology for the temporal assessment of such trajectories could serve as the preliminary basis of a disease prediction system., We received support from ISCIII-FEDER (PI13/00082, CP10/00524, CPII16/00026), IMI-JU under grants agreements no. 115372 (EMIF), resources composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D + i 2013-2016, funded by ISCIII and FEDER. Funding has been also received by the Marie-Curie UPFellowship Program.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Uncovering disease mechanisms through network biology in the era of next generation sequencing.

  • Piñero González, Janet, 1977-
  • Berenstein, Ariel José
  • González-Pérez, Abel
  • Chernomoretz, Ariel
  • Furlong, Laura I., 1971-
Characterizing the behavior of disease genes in the context of biological networks has the potential to shed light on disease mechanisms, and to reveal both new candidate disease genes and therapeutic targets. Previous studies addressing the network properties of disease genes have produced contradictory results. Here we have explored the causes of these discrepancies and assessed the relationship between the network roles of disease genes and their tolerance to deleterious germline variants in human populations leveraging on: the abundance of interactome resources, a comprehensive catalog of disease genes and exome variation data. We found that the most salient network features of disease genes are driven by cancer genes and that genes related to different types of diseases play network roles whose centrality is inversely correlated to their tolerance to likely deleterious germline mutations. This proved to be a multiscale signature, including global, mesoscopic and local network centrality features. Cancer driver genes, the most sensitive to deleterious variants, occupy the most central positions, followed by dominant disease genes and then by recessive disease genes, which are tolerant to variants and isolated within their network modules., We received support from UBACyT (20020130100582BA) and MinCyT (PICT2014-2701), ISCIII-FEDER (PI13/00082, CP10/00524), IMI-JU under grants agreements n° 115002 (eTOX), n° 115191 (Open PHACTS)], n° 115372 (EMIF) and n° 115735 (iPiE), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution, and the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a node of the Spanish National Institute of Bioinformatics (INB). A.G.-P. is supported by a Ramon y Cajal scholarship funded by the Spanish Ministry of Economy. The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Impact of simulated reduced injected dose on the assessment of amyloid PET scans

  • Young, Peter
  • Heeman, Fiona
  • Axelsson, Jan
  • Collij, Lyduine E.
  • Hitzel, Anne
  • Sanaat, Amirhossein
  • Niñerola-Baizán, Aida
  • Perissinotti, Andrés
  • Lubberink, Mark
  • Frisoni, Giovanni B.
  • Zaidi, Habib
  • Barkhof, Frederik
  • Farrar, Gill
  • Baker, Suzanne
  • Gispert, Juan Domingo
  • Garibotto, Valentina
  • Rieckmann, Anna
  • Schöll, Michael
  • AMYPAD Consortium
Purpose: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods: Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90-110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated. Results: At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [18F]flutemetamol and [18F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were < 1.5%. AUCs for discriminating Aβ- from Aβ + scans were high (AUC ≥ 0.94) across dose levels, and visual assessment showed intra-reader agreement of > 80% for both tracers. Conclusion: This proof-of-concept study showed that for both [18F]flutemetamol and [18F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances., Open access funding provided by University of Gothenburg. This project received funding from the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking (EMIF grant:115372) and the EU-EFPIA IMI-2 Joint Undertaking (grant:115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

psygenet2r: a R/Bioconductor package for the analysis of psychiatric disease genes

  • Gutiérrez Sacristán, Alba
  • Hernández Ferrer, Carles
  • González, Juan Ramón
  • Furlong, Laura I., 1971-
MOTIVATION: Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. RESULTS: We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. AVAILABILITY AND IMPLEMENTATION: The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html)., This work was supported by ISCIII-FEDER [PI13/00082, CP10/00524, CPII16/00026], MICINN [MTM2015-68140-R], IMI-JU under grants agreements no. 115191 (Open PHACTS), no. 115372 (EMIF), no. 115735 (iPiE), resources of which are composed of financial contribution from the EU-FP7 [FP7/2007–2013] and EFPIA companies in kind contribution, and the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of ELIXIR-ES and the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D+i 2013-2016, funded by ISCIII and FEDER. A.G.S. acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through the ‘María de Maeztu’ Programme for Units of Excellence in R&D [MDM-2014-0370].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Using Electronic Health Records to Assess Depression and Cancer Comorbidities

  • Mayer, Miguel Ángel, 1960-
  • Gutiérrez Sacristán, Alba
  • Leis Machín, Angela 1974-
  • De La Peña, Santiago
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Comorbid diseases are an important concern in oncology since they can affect the choice and effectiveness of treatment. What is particularly relevant is the fact that the diagnosis of depression in cancer patients has an important impact on the quality of life of these patients. Although there is no consensus about a specific relationship of depression with certain cancer types, some authors have proposed that depression constitutes a risk factor for cancer. The objective of this study is to identify the presence of comorbidities in a massive EHR system, between depression and the 10 most common cancers in women and men and to determine if there is a preferred temporal ordering in the co-occurrence of these diseases. All the cancers studied showed a significant co-occurrence with depression, more specifically, twice more frequent than what could be expected by chance. A preferred directionality was identified between some of the comorbid diseases, such as breast cancer followed by depression, and depression followed by either stomach cancer, colorectal cancer or lung cancer. Future work will address other potential factors that have an influence on the likelihood of suffering from depression in patients with cancer, such as drug therapies received, exposure to substance of abuse or other comorbidities., We received support from the IMI-JU under grant agreement no.115372 (EMIF), resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and from the EU H2020 Research & Innovation Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics: Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases.

  • Queralt Rosinach, Núria
  • Piñero González, Janet, 1977-
  • Bravo Serrano, Àlex, 1984-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
MOTIVATION: DisGeNET-RDF makes available knowledge on the genetic basis of human diseases in the Semantic Web. Gene-disease associations (GDAs) and their provenance metadata are published as human-readable and machine-processable web resources. The information on GDAs included in DisGeNET-RDF is interlinked to other biomedical databases to support the development of bioinformatics approaches for translational research through evidence-based exploitation of a rich and fully interconnected linked open data., We received support from ISCIII-FEDER (PI13/00082, CP10/00524), from the IMI-JU under grants agreements no. 115002 (eTOX), no. 115191 (Open PHACTS), no. 115372 (EMIF) and no. 115735 (iPiE), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contribution, and the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a node of the Spanish National Institute of Bioinformatics (INB).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Text mining and expert curation to develop a database on psychiatric diseases and their genes

  • Gutiérrez Sacristán, Alba
  • Bravo Serrano, Àlex, 1984-
  • Portero Tresserra, Marta
  • Valverde Granados, Olga
  • Leis Machín, Angela 1974-
  • Mayer, Miguel Ángel, 1960-
  • Warnault, Vincent
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Psychiatric disorders constitute one of the main causes of disability worldwide. During the past years, considerable research has been conducted on the genetic architecture of such diseases, although little understanding of their etiology has been achieved. The difficulty to access up-to-date, relevant genotype-phenotype information has hampered the application of this wealth of knowledge to translational research and clinical practice in order to improve diagnosis and treatment of psychiatric patients. PsyGeNET (http://www.psygenet.org/) has been developed with the aim of supporting research on the genetic architecture of psychiatric diseases, by providing integrated and structured accessibility to their genotype-phenotype association data, together with analysis and visualization tools. In this article, we describe the protocol developed for the sustainable update of this knowledge resource. It includes the recruitment of a team of domain experts in order to perform the curation of the data extracted by text mining. Annotation guidelines and a web-based annotation tool were developed to support the curators' tasks. A curation workflow was designed including a pilot phase and two rounds of curation and analysis phases. Negative evidence from the literature on gene-disease associ- ations (GDAs) was taken into account in the curation process. We report the results of the application of this workflow to the curation of GDAs for PsyGeNET, including the analysis of the inter-annotator agreement and suggest this model as a suitable approach for the sustainable development and update of knowledge resources. Database URL: http://www.psygenet.org. PsyGeNET corpus: http://www.psygenet.org/ds/PsyGeNET/results/psygenetCorpus.tar, We received support from ISCIII-FEDER (PI13/00082, CP10/00524, CPII16/00026), IMI-JU under grants agreements no. 115191 (Open PHACTS)] and no. 115372 (EMIF), resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D+i 2013-2016, funded by ISCIII and FEDER. MRA, SMR and MCBG are supported RD16/0017/0007; OV, FF and MT are supported by RD16/0017/0010; and AS and FJP are supported by RD16/0017/0001, by Instituto de Salud Carlos III, Red de Trastornos Adictivos (RTA-Retics-ISCIII). AGS acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through the 'María de Maeztu' Programme for Units of Excellence in R&D (MDM-2014-0370). Funding for open access: EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Discovery and validation of plasma proteomic biomarkers relating tobrain amyloid burden by SOMAscan assay

  • Shi, Liu
  • Molinuevo, José Luis
  • Nevado-Holgado, Alejo J.
Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition., This research was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013), and EFPIA companies’ in-kind contribution. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the 5th framework program (contract # 37670). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007, and #15005). R.V. is a senior clinical investigator of the Flemish Research Foundation (FWO). J.S. is currently an employee of UCB, Braine-l’Alleud, Belgium. The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The authors acknowledge the contribution of the personnel of the Genomic Service Facility at the VIB-U Antwerp Center for Molecular Neurology. The research at VIBCMN is funded in part by the University of Antwerp Research Fund. F.B. is supported by the NIHR biomedical research centre at UCLH. L.S. is funded by DPUK through MRC (grant no. MR/L023784/2) and the UK Medical Research Council Award to the University of Oxford (grant no. MC_PC_17215).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

PsyGeNET: a knowledge platform on psychiatric disorders and their genes

  • Gutiérrez Sacristán, Alba
  • Grosdidier, Solène
  • Valverde Granados, Olga
  • Torrens, Marta
  • Bravo Serrano, Àlex, 1984-
  • Piñero González, Janet, 1977-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
PsyGeNET (Psychiatric disorders and Genes association NETwork) is a knowledge platform for the exploratory analysis of psychiatric diseases and their associated genes. PsyGeNET is composed of a database and a web interface supporting data search, visualization, filtering and sharing. PsyGeNET integrates information from DisGeNET and data extracted from the literature by text mining, which has been curated by domain experts. It currently contains 2642 associations between 1271 genes and 37 psychiatric disease concepts. In its first release, PsyGeNET is focused on three psychiatric disorders: major depression, alcohol and cocaine use disorders. PsyGeNET represents a comprehensive, open access resource for the analysis of the molecular mechanisms underpinning psychiatric disorders and their comorbidities. AVAILABILITY AND IMPLEMENTATION: The PysGeNET platform is freely available at http://www.psygenet.org/. The PsyGeNET database is made available under the Open Database License (http://opendatacommons.org/licenses/odbl/1.0/). CONTACT: lfurlong@imim.es SUPPLEMENTARY INFORMATION:/nSupplementary data are available at Bioinformatics online., This work was supported by Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (CP10/00524, PI13/00082 and RD12/028/024 and RD12/0028/0009 Retics-RTA), MINECO (SAF2013-41761-R-Fondo Europeo de Desarrollo Regional), the Innovative Medicines Initiative Joint Undertaking (no. 115372, EMIF and no. 115191, Open PHACTS), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. The Research Programme on Biomedical Informatics (GRIB) is a node of the Spanish National Institute of Bioinformatics (INB).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Quality of Hospital Electronic Health Record (EHR) Data Based on the International Consortium for Health Outcomes Measurement (ICHOM) in Heart Failure: Pilot Data Quality Assessment Study

  • Aerts, Hannelore
  • Kalra, Dipak
  • Sáez Silvestre, Carlos
  • Ramírez-Anguita, Juan Manuel
  • Mayer, Miguel-Angel
  • Durá-Hernández, Marta
  • Thienpont, Geert
  • Coorevits, Pascal
  • Garcia-Gomez, Juan M
[EN] Background: There is increasing recognition that health care providers need to focus attention, and be judged against, the impact they have on the health outcomes experienced by patients. The measurement of health outcomes as a routine part of clinical documentation is probably the only scalable way of collecting outcomes evidence, since secondary data collection is expensive and error-prone. However, there is uncertainty about whether routinely collected clinical data within electronic health record (EHR) systems includes the data most relevant to measuring and comparing outcomes and if those items are collected to a good enough data quality to be relied upon for outcomes assessment, since several studies have pointed out significant issues regarding EHR data availability and quality. Objective: In this paper, we first describe a practical approach to data quality assessment of health outcomes, based on a literature review of existing frameworks for quality assessment of health data and multistakeholder consultation. Adopting this approach, we performed a pilot study on a subset of 21 International Consortium for Health Outcomes Measurement (ICHOM) outcomes data items from patients with congestive heart failure. Methods: All available registries compatible with the diagnosis of heart failure within an EHR data repository of a general hospital (142,345 visits and 12,503 patients) were extracted and mapped to the ICHOM format. We focused our pilot assessment on 5 commonly used data quality dimensions: completeness, correctness, consistency, uniqueness, and temporal stability. Results: We found high scores (>95%) for the consistency, completeness, and uniqueness dimensions. Temporal stability analyses showed some changes over time in the reported use of medication to treat heart failure, as well as in the recording of past medical conditions. Finally, the investigation of data correctness suggested several issues concerning the characterization of missing data values. Many of these issues appear to be introduced while mapping the IMASIS-2 relational database contents to the ICHOM format, as the latter requires a level of detail that is not explicitly available in the coded data of an EHR. Conclusions: Overall, results of this pilot study revealed good data quality for the subset of heart failure outcomes collected at the Hospital del Mar. Nevertheless, some important data errors were identified that were caused by fundamentally different data collection practices in routine clinical care versus research, for which the ICHOM standard set was originally developed. To truly examine to what extent hospitals today are able to routinely collect the evidence of their success in achieving good health outcomes, future research would benefit from performing more extensive data quality assessments, including all data items from the ICHOM standards set and across multiple hospitals., MAM and JMRA had support from the Innovative Medicines Initiative Joint Under-taking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies. The funders were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Mechanotransduction in tumor dynamics modeling

  • Blanco, Beatriz
  • Gómez, Héctor
  • Melchor, Juan
  • Palma, Roberto
  • Soler, Juan
  • Rus, Guillermo
[Abstract:] Mechanotherapy is a groundbreaking approach to impact carcinogenesis. Cells sense and respond to mechanical stimuli, translating them into biochemical signals in a process known as mechanotransduction. The impact of stress on tumor growth has been studied in the last three decades, and many papers highlight the role of mechanics as a critical self-inducer of tumor fate at the in vitro and in vivo biological levels. Meanwhile, mathematical models attempt to determine laws to reproduce tumor dynamics. This review discusses biological mechanotransduction mechanisms and mathematical-biomechanical models together. The aim is to provide a common framework for the different approaches that have emerged in the literature from the perspective of tumor avascularity and to provide insight into emerging mechanotherapies that have attracted interest in recent years., This paper has been partially supported by the MINECO-FEDER (Spain) research grant number EQC2018-004508-P, PID2019-106947RA-C22 (B.B., J.M., G.R.) and RTI2018-098850-B-I00 (J.S.). This study was also funded by Ministry of Science, Innovation and Universities of Spain, project numbers PID2020-115372RB-I00 (B.B., G.R.), Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía P18-RT-1653 (B.B., J.M., G.R.), PY18-RT-2422 & B-FQM-580-UGR20 (J.S.), and by Consejería de Universidad, Investigación e Innovación from Junta de Andalucía, P21.00182 (B.B., J.M., G.R.). Lastly, B.B. research was granted by the Ministry of Science, Innovation and Universities of Spain, FPU2017/01415. Funding for open access charge: Universidad de Granada / CBUA. Figures were created with Biorender.com., Junta de Andalucía; P18-RT-1653, Junta de Andalucía; PY18-RT-2422, Junta de Andalucía; B-FQM-580-UGR20, Junta de Andalucía; P21.00182
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

psygenet2r: a R/Bioconductor package for the analysis of psychiatric disease genes

  • Gutiérrez Sacristán, Alba
  • Hernández Ferrer, Carles
  • González, Juan Ramón
  • Furlong, Laura I.
Motivation: Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. Results: We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. Availability: The package is implemented in R and is available under MIT license from Bioconductor ( http://bioconductor.org/packages/release/bioc/html/psygenet2r.html ). Supplementary information: Supplementary data are available at Bioinformatics online.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

  • Shi, Liu
  • Winchester, Laura M.
  • Liu, Benjamine Y.
  • Killik, Richard
  • Ribe, Elena
  • Westwood, Sarah
  • Baird, Alison L.
  • Buckley, Noel J.
  • Hong, Shengjun
  • Dobricic, Valerija
  • Kilpert, Fabian
  • Franke, Andre
  • Kiddle, Steven
  • Sattlecker, Martina
  • Dobson, Richard
  • Cuadrado, Antonio
  • Hye, Abdul
  • Ashton, Nicholas J.
  • Morgan, Angharad R.
  • Bos, Isabelle
  • Vos, Stephanie J. B.
  • Kate, Mara ten
  • Scheltens, Philip
  • Vandenberghe, Rik
  • Gabel, Silvy
  • Meersmans, Karen
  • Engelborghs, Sebastiaan
  • Roeck, Ellen E. De
  • Sleegersr, Kristel
  • Frisoni, Giovanni B.
  • Blin, Olivier
  • Richardson, Jill C.
  • Bordet, Regis
  • Molinuevo, José Luis
  • Rami, Lorena
  • Wallin, Anders
  • Kettunen, Petronella
  • Tsolaki, Magda
  • Verhey, Frans
  • Lleó, Alberto
  • Alcolea, Daniel
  • Popp, Julius
  • Peyratout, Gwendoline
  • Martinez-Lage, Pablo
  • Tainta, Mikel
  • Johannsen, Peter
  • Teunissen, Charlotte E.
  • Freund-Levi, Yvonne
  • Frolich, Lutz
  • Legido-Quigley, Cristina
  • Barkhof, Frederik
  • Blennow, Kaj
  • Rasmussen, Katrine Laura
  • Nordestgaardv, Børge Grønne
  • Frikke-Schmidtu, Ruth
  • Fallgaard Nielsen, Sune
  • Soininen, Hilkka
  • Vellas, Bruno
  • Kloszewska, Iwona
  • Mecocci, Patrizia
  • Zetterberg, Henrik
  • Morgan, B. Paul
  • Strefferq, Johannes
  • Jelle Visser, Pieter
  • Bertramc, Lars
  • Nevado-Holgado, Alejo J.
  • Lovestone, Simon
© 2020 – IOS Press and the authors., [Background]: Previous studies suggest that Dickkopf-1 (DKK1), an inhibitor of Wnt signaling, plays a role in amyloid-induced toxicity and hence Alzheimer’s disease (AD). However, the effect of DKK1 expression on protein expression, and whether such proteins are altered in disease, is unknown. [Objective]: We aim to test whether DKK1 induced protein signature obtained in vitro were associated with markers of AD pathology as used in the amyloid/tau/neurodegeneration (ATN) framework as well as with clinical outcomes. [Methods]: We first overexpressed DKK1 in HEK293A cells and quantified 1,128 proteins in cell lysates using aptamer capture arrays (SomaScan) to obtain a protein signature induced by DKK1. We then used the same assay to measure the DKK1-signature proteins in human plasma in two large cohorts, EMIF (n = 785) and ANM (n = 677). [Results]: We identified a 100-protein signature induced by DKK1 in vitro. Subsets of proteins, along with age and apolipoprotein E ɛ4 genotype distinguished amyloid pathology (A + T–N–, A+T+N–, A+T–N+, and A+T+N+) from no AD pathology (A–T–N–) with an area under the curve of 0.72, 0.81, 0.88, and 0.85, respectively. Furthermore, we found that some signature proteins (e.g., Complement C3 and albumin) were associated with cognitive score and AD diagnosis in both cohorts. [Conclusions]: Our results add further evidence for a role of DKK regulation of Wnt signaling in AD and suggest that DKK1 induced signature proteins obtained in vitro could reflect theATNframework as well as predict disease severity and progression in vivo., This research was conducted as part of the EMIF-AD project which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n° 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the 5th framework program (contract # 37670). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007 and #15005). The Lausanne cohort study was supported by a grant from the Swiss National Research Foundation to JP (SNF 320030_141179). RV is a senior clinical investigator of the Flemish Research Foundation (FWO). JS is currently an employee of UCB, Braine-l’Alleud, Belgium. The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). We acknowledge the contribution of the personnel of the Genomic Service Facility at the VIB-U Antwerp Center for Molecular Neurology. The research at VIB-CMN is funded in part by the University of Antwerp Research Fund. FB is supported by the NIHR biomedical research centre at UCLH. RD is supported by Health Data Research UK, the National Institute for Health Research (NIHR) Biomedical Research Centre at South London, Maudsley NHS Foundation Trust, King’s College London and the NIHR University College London Hospitals Biomedical Research Centre. LS is funded by DPUK through MRC (grant no. MR/L023784/2) and the UK Medical Research Council Award to the University of Oxford (grant no. MC_PC_17215). Also support was received from the NIHR Biomedical Research Centre at Oxford Health NHS Foundation Trust.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysozyme crystallization in hydrogel media under ultrasound irradiation

  • Savchenko, Mariia
  • Hurtado, Manuel
  • Lopez-Lopez, Modesto T.
  • Rus, Guillermo
  • Álvarez de Cienfuegos, Luis
  • Melchor, Juan
  • Gavira Gallardo, J. A.
Sonocrystallization implies the application of ultrasound radiation to control the nucleation and crystal growth depending on the actuation time and intensity. Its application allows to induce nucleation at lower supersaturations than required under standard conditions. Although extended in inorganic and organic crystallization, it has been scarcely explored in protein crystallization. Now, that industrial protein crystallization is gaining momentum, the interest on new ways to control protein nucleation and crystal growth is advancing. In this work we present the development of a novel ultrasound bioreactor to study its influence on protein crystallization in agarose gel. Gel media minimize convention currents and sedimentation, favoring a more homogeneous and stable conditions to study the effect of an externally generated low energy ultrasonic irradiation on protein crystallization avoiding other undesired effects such as temperature increase, introduction of surfaces which induce nucleation, destructive cavitation phenomena, etc. In-depth statistical analysis of the results has shown that the impact of ultrasound in gel media on crystal size populations are statistically significant and reproducible., This study was supported by project PID2020-118498GB-I00, PID2020-116261GB-I00 and PID2020-115372RB-I00 funded by MCIN/AEI/ 10.13039/501100011033/ and PID2019-106947RA-C22 funded by MCIN/AEI/ 10.13039/501100011033/FEDER “Una manera de hacer Europa”, Spain, and by FEDER/Junta de Andalucía-Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Spain) projects A-FQM-340-UGR20, P18-FR-3533, P18-RT-1653, B-TEP-026-UGR18.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Using Electronic Health Records to Assess Depression and Cancer Comorbidities

  • Mayer, Miguel Ángel, 1960-
  • Gutiérrez Sacristán, Alba
  • Leis Machín, Angela 1974-
  • De La Peña, Santiago
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Comorbid diseases are an important concern in oncology since they can affect the choice and effectiveness of treatment. What is particularly relevant is the fact that the diagnosis of depression in cancer patients has an important impact on the quality of life of these patients. Although there is no consensus about a specific relationship of depression with certain cancer types, some authors have proposed that depression constitutes a risk factor for cancer. The objective of this study is to identify the presence of comorbidities in a massive EHR system, between depression and the 10 most common cancers in women and men and to determine if there is a preferred temporal ordering in the co-occurrence of these diseases. All the cancers studied showed a significant co-occurrence with depression, more specifically, twice more frequent than what could be expected by chance. A preferred directionality was identified between some of the comorbid diseases, such as breast cancer followed by depression, and depression followed by either stomach cancer, colorectal cancer or lung cancer. Future work will address other potential factors that have an influence on the likelihood of suffering from depression in patients with cancer, such as drug therapies received, exposure to substance of abuse or other comorbidities., We received support from the IMI-JU under grant agreement no.115372 (EMIF), resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and from the EU H2020 Research & Innovation Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics: Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of cerebral blood flow and amyloid load on SUVR bias

  • Heeman, Fiona
  • Yaqub, Maqsood
  • Hendriks, Janine
  • van Berckel, Bart N. M.
  • Collij, Lyduine E.
  • Gray, Katherine R.
  • Manber, Richard
  • Wolz, Robin
  • Garibotto, Valentina
  • Wimberley, Catriona
  • Ritchie, Craig
  • Barkhof, Frederik
  • Gispert, Juan Domingo
  • Vállez García, David
  • Lopes Alves, Isadora
  • Lammertsma, Adriaan A.
  • AMYPAD Consortium
Background: despite its widespread use, the semi-quantitative standardized uptake value ratio (SUVR) may be biased compared with the distribution volume ratio (DVR). This bias may be partially explained by changes in cerebral blood flow (CBF) and is likely to be also dependent on the extent of the underlying amyloid-β (Aβ) burden. This study aimed to compare SUVR with DVR and to evaluate the effects of underlying Aβ burden and CBF on bias in SUVR in mainly cognitively unimpaired participants. Participants were scanned according to a dual-time window protocol, with either [18F]flutemetamol (N = 90) or [18F]florbetaben (N = 31). The validated basisfunction-based implementation of the two-step simplified reference tissue model was used to derive DVR and R1 parametric images, and SUVR was calculated from 90 to 110 min post-injection, all with the cerebellar grey matter as reference tissue. First, linear regression and Bland-Altman analyses were used to compare (regional) SUVR with DVR. Then, generalized linear models were applied to evaluate whether (bias in) SUVR relative to DVR could be explained by R1 for the global cortical average (GCA), precuneus, posterior cingulate, and orbitofrontal region. Results: despite high correlations (GCA: R2 ≥ 0.85), large overestimation and proportional bias of SUVR relative to DVR was observed. Negative associations were observed between both SUVR or SUVRbias and R1, albeit non-significant. Conclusion: the present findings demonstrate that bias in SUVR relative to DVR is strongly related to underlying Aβ burden. Furthermore, in a cohort consisting mainly of cognitively unimpaired individuals, the effect of relative CBF on bias in SUVR appears limited. EudraCT Number: 2018-002277-22, registered on: 25-06-2018., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this project received funding from the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking (EMIF grant:115372) and the EU-EFPIA IMI-2 Joint Undertaking (grant:115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. FB is supported by the NIHR biomedical research centre at UCLH. JDG holds a ‘Ramón y Cajal’ fellowship (RYC-2013-13054) from the Spanish Ministry of Science, Innovation and Universities. VG reports grants from the Swiss National Science Foundation (projects:320030_169876, 320030_185028 and IZSEZ0_188355) and the Velux foundation (project:1123).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource

  • Perera, Gayan
  • Pedersen, Lars
  • Ansel, David
  • Alexander, Myriam
  • Arrighi, H. Michael
  • Avillach, Paul
  • Foskett, Nadia
  • Gini, Rosa
  • Gordon, Mark F.
  • Gungabissoona, Usha
  • Mayer, Miguel Ángel, 1960-
  • Novak, Gerald
  • Rijnbeek, Peter
  • Trifirò, Gianluca
  • van der Lei, Johan
  • Visser, Pieter Jelle
  • Stewart, Robert
INTRODUCTION: The European Medical Information Framework consortium has assembled electronic health record (EHR) databases for dementia research. We calculated dementia prevalence and incidence in 25 million persons from 2004 to 2012. METHODS: Six EHR databases (three primary care and three secondary care) from five countries were interrogated. Dementia was ascertained by consensus harmonization of clinical/diagnostic codes. Annual period prevalences and incidences by age and gender were calculated and meta-analyzed. RESULTS: The six databases contained 138,625 dementia cases. Age-specific prevalences were around 30% of published estimates from community samples and incidences were around 50%. Pooled prevalences had increased from 2004 to 2012 in all age groups but pooled incidences only after age 75 years. Associations with age and gender were stable over time. DISCUSSION: The European Medical Information Framework initiative supports EHR data on unprecedented number of people with dementia. Age-specific prevalences and incidences mirror estimates from community samples in pattern at levels that are lower but increasing over time., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under European Medical Informatics Framework (EMIF) grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind contribution. R.S. and G.P. are partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

  • Stamate, Daniel
  • Molinuevo, José Luis
  • Legido-Quigley, Cristina
Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers. This study analyzed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n = 883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV). On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively. This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disorders., The present study was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007–2013) and EFPIA companies’ in-kind contribution. The DESCRIPA study was funded by the European Commission within the fifth framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the fifth framework program (contract no. 37670). The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01. 41142.001.H). Kristel Sleegers is supported by the Research Fund of the University of Antwerp. Daniel Stamate is supported by the Alzheimer’s Research UK (ARUK-PRRF2017-012).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

psygenet2r: a R/Bioconductor package for the analysis of psychiatric disease genes

  • Gutiérrez Sacristán, Alba
  • Hernández Ferrer, Carles
  • González, Juan Ramón
  • Furlong, Laura I.
Motivation: Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. Results: We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. Availability: The package is implemented in R and is available under MIT license from Bioconductor ( http://bioconductor.org/packages/release/bioc/html/psygenet2r.html ). Supplementary information: Supplementary data are available at Bioinformatics online.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of simulated reduced injected dose on the assessment of amyloid PET scans

  • Young, Peter
  • Heeman, Fiona
  • Axelsson, Jan
  • Collij, Lyduine E.
  • Hitzel, Anne
  • Sanaat, Amirhossein
  • Niñerola-Baizán, Aida
  • Perissinotti, Andrés
  • Lubberink, Mark
  • Frisoni, Giovanni B.
  • Zaidi, Habib
  • Barkhof, Frederik
  • Farrar, Gill
  • Baker, Suzanne
  • Gispert, Juan Domingo
  • Garibotto, Valentina
  • Rieckmann, Anna
  • Schöll, Michael
  • AMYPAD Consortium
Purpose: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods: Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90-110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated. Results: At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [18F]flutemetamol and [18F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were < 1.5%. AUCs for discriminating Aβ- from Aβ + scans were high (AUC ≥ 0.94) across dose levels, and visual assessment showed intra-reader agreement of > 80% for both tracers. Conclusion: This proof-of-concept study showed that for both [18F]flutemetamol and [18F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances., Open access funding provided by University of Gothenburg. This project received funding from the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking (EMIF grant:115372) and the EU-EFPIA IMI-2 Joint Undertaking (grant:115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Federated discovery and sharing of genomic data using Beacons

  • Fiume, Marc
  • Rambla de Argila, Jordi
  • Torre, Sabela de la
  • Scollen, Serena
M.F. and S.O.M.D. are supported by Genome Quebec, Genome Canada, the Government of Canada, and the Ministère de l’Économie, Innovation et Exportation du Québec (Can-SHARE grant 141210); S.O.M.D. is supported by the Canadian Institutes of Health Research (grants EP1-120608; EP2-120609); M.H. is supported by BD2K NIH/NCI 5U54HG007990-02; S. Scollen, S.V., M.B., I.L., J.T., S.U.-R., S.d.l.T., M.L., H.S. and the EGA are supported by ELIXIR, the research infrastructure for life-science data. This work was supported by ELIXIR-EXCELERATE, funded by the European Commission within the Research Infrastructures programme of Horizon 2020, grant agreement number 676559 (J.D.S., I.L.), the Wellcome Trust grant numbers WT201535/Z/16/Z (P.F.) and WT098051 (S.K., D.L., P.F.). A.J.B. is supported by the European Union FP7 Programme ‘EMIF’ IMI-JU grant no. 115372, and H2020 Programme ‘GCOF’ grant no. 643439
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records

  • Perera, Gayan
  • Rijnbeek, Peter
  • Alexander, Myriam
  • Ansel, David
  • Avillach, Paul
  • Duarte Salles, Talita, 1985-
  • Gordon, Mark F.
  • Lapi, Francesco
  • Mayer, Miguel Ángel, 1960-
  • Pasqua, Alessandro
  • Pedersen, Lars
  • van der Lei, Johan
  • Visser, Pieter Jelle
  • Stewart, Robert
Objective: The objective of the study is to compare body mass index (BMI), systolic/diastolic blood pressure (SBP/DBP) and serum total cholesterol levels between dementia cases and controls at multiple time intervals prior to dementia onset, and to test time interval as a modifying factor for these associations. Design: Case-control study. Setting: Six European electronic health records databases. Participants: 291 780 cases at the date of first-recorded dementia diagnosis, compared with 29 170 549 controls randomly selected from the same databases, age matched and sex matched at this index date. Exposure: The following measures were extracted whenever recorded within each dataset: BMI (kg/m2), SBP and DBP (mm Hg) and serum total cholesterol (mmol/L). Levels for each of these variables were defined within six 2-year time intervals over the 12 years prior to the index date. Main outcomes: Case-control differences in exposures of interest were modelled for each time period and adjusted for demographic and clinical factors (ischaemic/unspecified stroke, type 2 diabetes mellitus, acute myocardial infarction, hypertension diagnosis, antihypertensive medication, cholesterol-lowering medication). Coefficients and interactions with time period were meta-analysed across the six databases. Results: Mean BMI (coefficient -1.16 kg/m2; 95% CI -1.38 to 0.93) and SBP (-2.83 mm Hg; 95% CI -4.49 to -1.16) were lower in cases at diagnosis, and case-control differences were greater in more recent time periods, as indicated by significant case-x-time interaction and case-x-time-squared interaction terms. Time variations in coefficients for cholesterol levels were less consistent between databases and those for DBP were largely not significant. Conclusion: Routine clinical data show emerging divergence in levels of BMI and SBP prior to the diagnosis of dementia but less evidence for DBP or total cholesterol levels. These divergences should receive at least some consideration in routine dementia risk screening, although underlying mechanisms still require further investigation., The research leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under EMIF grant agreement n° 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. RS and GP are part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Text mining and expert curation to develop a database on psychiatric diseases and their genes

  • Gutiérrez Sacristán, Alba
  • Bravo Serrano, Àlex, 1984-
  • Portero Tresserra, Marta
  • Valverde Granados, Olga
  • Leis Machín, Angela 1974-
  • Mayer, Miguel Ángel, 1960-
  • Warnault, Vincent
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Psychiatric disorders constitute one of the main causes of disability worldwide. During the past years, considerable research has been conducted on the genetic architecture of such diseases, although little understanding of their etiology has been achieved. The difficulty to access up-to-date, relevant genotype-phenotype information has hampered the application of this wealth of knowledge to translational research and clinical practice in order to improve diagnosis and treatment of psychiatric patients. PsyGeNET (http://www.psygenet.org/) has been developed with the aim of supporting research on the genetic architecture of psychiatric diseases, by providing integrated and structured accessibility to their genotype-phenotype association data, together with analysis and visualization tools. In this article, we describe the protocol developed for the sustainable update of this knowledge resource. It includes the recruitment of a team of domain experts in order to perform the curation of the data extracted by text mining. Annotation guidelines and a web-based annotation tool were developed to support the curators' tasks. A curation workflow was designed including a pilot phase and two rounds of curation and analysis phases. Negative evidence from the literature on gene-disease associ- ations (GDAs) was taken into account in the curation process. We report the results of the application of this workflow to the curation of GDAs for PsyGeNET, including the analysis of the inter-annotator agreement and suggest this model as a suitable approach for the sustainable development and update of knowledge resources. Database URL: http://www.psygenet.org. PsyGeNET corpus: http://www.psygenet.org/ds/PsyGeNET/results/psygenetCorpus.tar, We received support from ISCIII-FEDER (PI13/00082, CP10/00524, CPII16/00026), IMI-JU under grants agreements no. 115191 (Open PHACTS)] and no. 115372 (EMIF), resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D+i 2013-2016, funded by ISCIII and FEDER. MRA, SMR and MCBG are supported RD16/0017/0007; OV, FF and MT are supported by RD16/0017/0010; and AS and FJP are supported by RD16/0017/0001, by Instituto de Salud Carlos III, Red de Trastornos Adictivos (RTA-Retics-ISCIII). AGS acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through the 'María de Maeztu' Programme for Units of Excellence in R&D (MDM-2014-0370). Funding for open access: EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PsyGeNET: a knowledge platform on psychiatric disorders and their genes

  • Gutiérrez Sacristán, Alba
  • Grosdidier, Solène
  • Valverde Granados, Olga
  • Torrens, Marta
  • Bravo Serrano, Àlex, 1984-
  • Piñero González, Janet, 1977-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
PsyGeNET (Psychiatric disorders and Genes association NETwork) is a knowledge platform for the exploratory analysis of psychiatric diseases and their associated genes. PsyGeNET is composed of a database and a web interface supporting data search, visualization, filtering and sharing. PsyGeNET integrates information from DisGeNET and data extracted from the literature by text mining, which has been curated by domain experts. It currently contains 2642 associations between 1271 genes and 37 psychiatric disease concepts. In its first release, PsyGeNET is focused on three psychiatric disorders: major depression, alcohol and cocaine use disorders. PsyGeNET represents a comprehensive, open access resource for the analysis of the molecular mechanisms underpinning psychiatric disorders and their comorbidities. AVAILABILITY AND IMPLEMENTATION: The PysGeNET platform is freely available at http://www.psygenet.org/. The PsyGeNET database is made available under the Open Database License (http://opendatacommons.org/licenses/odbl/1.0/). CONTACT: lfurlong@imim.es SUPPLEMENTARY INFORMATION:/nSupplementary data are available at Bioinformatics online., This work was supported by Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (CP10/00524, PI13/00082 and RD12/028/024 and RD12/0028/0009 Retics-RTA), MINECO (SAF2013-41761-R-Fondo Europeo de Desarrollo Regional), the Innovative Medicines Initiative Joint Undertaking (no. 115372, EMIF and no. 115191, Open PHACTS), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. The Research Programme on Biomedical Informatics (GRIB) is a node of the Spanish National Institute of Bioinformatics (INB).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Discovery and validation of plasma proteomic biomarkers relating tobrain amyloid burden by SOMAscan assay

  • Shi, Liu
  • Molinuevo, José Luis
  • Nevado-Holgado, Alejo J.
Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition., This research was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013), and EFPIA companies’ in-kind contribution. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the 5th framework program (contract # 37670). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007, and #15005). R.V. is a senior clinical investigator of the Flemish Research Foundation (FWO). J.S. is currently an employee of UCB, Braine-l’Alleud, Belgium. The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The authors acknowledge the contribution of the personnel of the Genomic Service Facility at the VIB-U Antwerp Center for Molecular Neurology. The research at VIBCMN is funded in part by the University of Antwerp Research Fund. F.B. is supported by the NIHR biomedical research centre at UCLH. L.S. is funded by DPUK through MRC (grant no. MR/L023784/2) and the UK Medical Research Council Award to the University of Oxford (grant no. MC_PC_17215).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases.

  • Queralt Rosinach, Núria
  • Piñero González, Janet, 1977-
  • Bravo Serrano, Àlex, 1984-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
MOTIVATION: DisGeNET-RDF makes available knowledge on the genetic basis of human diseases in the Semantic Web. Gene-disease associations (GDAs) and their provenance metadata are published as human-readable and machine-processable web resources. The information on GDAs included in DisGeNET-RDF is interlinked to other biomedical databases to support the development of bioinformatics approaches for translational research through evidence-based exploitation of a rich and fully interconnected linked open data., We received support from ISCIII-FEDER (PI13/00082, CP10/00524), from the IMI-JU under grants agreements no. 115002 (eTOX), no. 115191 (Open PHACTS), no. 115372 (EMIF) and no. 115735 (iPiE), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contribution, and the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a node of the Spanish National Institute of Bioinformatics (INB).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quality of hospital electronic health record (EHR) data based on the international consortium for health outcomes measurement (ICHOM) in heart failure: pilot data quality assessment study

  • Aerts, Hannelore
  • Kalra, Dipak
  • Sáez, Carlos
  • Ramírez Anguita, Juan Manuel
  • Mayer, Miguel Ángel, 1960-
  • García-Gómez, Juan M.
  • Durà-Hernández, Marta
  • Thienpont, Geert
  • Coorevits, Pascal
Background: There is increasing recognition that health care providers need to focus attention, and be judged against, the impact they have on the health outcomes experienced by patients. The measurement of health outcomes as a routine part of clinical documentation is probably the only scalable way of collecting outcomes evidence, since secondary data collection is expensive and error-prone. However, there is uncertainty about whether routinely collected clinical data within electronic health record (EHR) systems includes the data most relevant to measuring and comparing outcomes and if those items are collected to a good enough data quality to be relied upon for outcomes assessment, since several studies have pointed out significant issues regarding EHR data availability and quality. Objective: In this paper, we first describe a practical approach to data quality assessment of health outcomes, based on a literature review of existing frameworks for quality assessment of health data and multistakeholder consultation. Adopting this approach, we performed a pilot study on a subset of 21 International Consortium for Health Outcomes Measurement (ICHOM) outcomes data items from patients with congestive heart failure. Methods: All available registries compatible with the diagnosis of heart failure within an EHR data repository of a general hospital (142,345 visits and 12,503 patients) were extracted and mapped to the ICHOM format. We focused our pilot assessment on 5 commonly used data quality dimensions: completeness, correctness, consistency, uniqueness, and temporal stability. Results: We found high scores (>95%) for the consistency, completeness, and uniqueness dimensions. Temporal stability analyses showed some changes over time in the reported use of medication to treat heart failure, as well as in the recording of past medical conditions. Finally, the investigation of data correctness suggested several issues concerning the characterization of missing data values. Many of these issues appear to be introduced while mapping the IMASIS-2 relational database contents to the ICHOM format, as the latter requires a level of detail that is not explicitly available in the coded data of an EHR. Conclusions: Overall, results of this pilot study revealed good data quality for the subset of heart failure outcomes collected at the Hospital del Mar. Nevertheless, some important data errors were identified that were caused by fundamentally different data collection practices in routine clinical care versus research, for which the ICHOM standard set was originally developed. To truly examine to what extent hospitals today are able to routinely collect the evidence of their success in achieving good health outcomes, future research would benefit from performing more extensive data quality assessments, including all data items from the ICHOM standards set and across multiple hospitals., MAM and JMRA had support from the Innovative Medicines Initiative Joint Under-taking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies. The funders were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Uncovering disease mechanisms through network biology in the era of next generation sequencing.

  • Piñero González, Janet, 1977-
  • Berenstein, Ariel José
  • González-Pérez, Abel
  • Chernomoretz, Ariel
  • Furlong, Laura I., 1971-
Characterizing the behavior of disease genes in the context of biological networks has the potential to shed light on disease mechanisms, and to reveal both new candidate disease genes and therapeutic targets. Previous studies addressing the network properties of disease genes have produced contradictory results. Here we have explored the causes of these discrepancies and assessed the relationship between the network roles of disease genes and their tolerance to deleterious germline variants in human populations leveraging on: the abundance of interactome resources, a comprehensive catalog of disease genes and exome variation data. We found that the most salient network features of disease genes are driven by cancer genes and that genes related to different types of diseases play network roles whose centrality is inversely correlated to their tolerance to likely deleterious germline mutations. This proved to be a multiscale signature, including global, mesoscopic and local network centrality features. Cancer driver genes, the most sensitive to deleterious variants, occupy the most central positions, followed by dominant disease genes and then by recessive disease genes, which are tolerant to variants and isolated within their network modules., We received support from UBACyT (20020130100582BA) and MinCyT (PICT2014-2701), ISCIII-FEDER (PI13/00082, CP10/00524), IMI-JU under grants agreements n° 115002 (eTOX), n° 115191 (Open PHACTS)], n° 115372 (EMIF) and n° 115735 (iPiE), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution, and the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a node of the Spanish National Institute of Bioinformatics (INB). A.G.-P. is supported by a Ramon y Cajal scholarship funded by the Spanish Ministry of Economy. The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project.

  • Roberto, Giuseppe
  • Mayer, Miguel Ángel, 1960-
  • Gini, Rosa
Due to the heterogeneity of existing European sources of observational healthcare data, data source-tailored choices are needed to execute multi-data source, multi-national epidemiological studies. This makes transparent documentation paramount. In this proof-of-concept study, a novel standard data derivation procedure was tested in a set of heterogeneous data sources. Identification of subjects with type 2 diabetes (T2DM) was the test case. We included three primary care data sources (PCDs), three record linkage of administrative and/or registry data sources (RLDs), one hospital and one biobank. Overall, data from 12 million subjects from six European countries were extracted. Based on a shared event definition, sixteeen standard algorithms (components) useful to identify T2DM cases were generated through a top-down/bottom-up iterative approach. Each component was based on one single data domain among diagnoses, drugs, diagnostic test utilization and laboratory results. Diagnoses-based components were subclassified considering the healthcare setting (primary, secondary, inpatient care). The Unified Medical Language System was used for semantic harmonization within data domains. Individual components were extracted and proportion of population identified was compared across data sources. Drug-based components performed similarly in RLDs and PCDs, unlike diagnoses-based components. Using components as building blocks, logical combinations with AND, OR, AND NOT were tested and local experts recommended their preferred data source-tailored combination. The population identified per data sources by resulting algorithms varied from 3.5% to 15.7%, however, age-specific results were fairly comparable. The impact of individual components was assessed: diagnoses-based components identified the majority of cases in PCDs (93-100%), while drug-based components were the main contributors in RLDs (81-100%). The proposed data derivation procedure allowed the generation of data source-tailored case-finding algorithms in a standardized fashion, facilitated transparent documentation of the process and benchmarking of data sources, and provided bases for interpretation of possible inter-data source inconsistency of findings in future studies., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking (http://www.imi.europa.eu/) under European Medical Information Framework grant agreement no. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Association companies’ in kind contribution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Pfizer Worldwide Research and Development, GlaxoSmithKline, Cegedim Strategic Data Medical Research Ltd and Janssen provided support in the form of salaries for AKL, PE, DA and MJS, respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

psygenet2r: a R/Bioconductor package for the analysis of psychiatric disease genes

  • Gutiérrez Sacristán, Alba
  • Hernández Ferrer, Carles
  • González, Juan Ramón
  • Furlong, Laura I., 1971-
MOTIVATION: Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. RESULTS: We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. AVAILABILITY AND IMPLEMENTATION: The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html)., This work was supported by ISCIII-FEDER [PI13/00082, CP10/00524, CPII16/00026], MICINN [MTM2015-68140-R], IMI-JU under grants agreements no. 115191 (Open PHACTS), no. 115372 (EMIF), no. 115735 (iPiE), resources of which are composed of financial contribution from the EU-FP7 [FP7/2007–2013] and EFPIA companies in kind contribution, and the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of ELIXIR-ES and the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D+i 2013-2016, funded by ISCIII and FEDER. A.G.S. acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through the ‘María de Maeztu’ Programme for Units of Excellence in R&D [MDM-2014-0370].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-based study

  • Giannoula, Alexia
  • Gutiérrez Sacristán, Alba
  • Bravo Serrano, Àlex, 1984-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Time is a crucial parameter in the assessment of comorbidities in population-based studies, as it permits to identify more complex disease patterns apart from the pairwise disease associations. So far, it has been, either, completely ignored or only, taken into account by assessing the temporal directionality of identified comorbidity pairs. In this work, a novel time-analysis framework is presented for large-scale comorbidity studies. The disease-history vectors of patients of a regional Spanish health dataset are represented as time sequences of ordered disease diagnoses. Statistically significant pairwise disease associations are identified and their temporal directionality is assessed. Subsequently, an unsupervised clustering algorithm, based on Dynamic Time Warping, is applied on the common disease trajectories in order to group them according to the temporal patterns that they share. The proposed methodology for the temporal assessment of such trajectories could serve as the preliminary basis of a disease prediction system., We received support from ISCIII-FEDER (PI13/00082, CP10/00524, CPII16/00026), IMI-JU under grants agreements no. 115372 (EMIF), resources composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D + i 2013-2016, funded by ISCIII and FEDER. Funding has been also received by the Marie-Curie UPFellowship Program.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

  • Hong, Shengjun
  • Dobricic, Valerija|||0000-0001-8559-1097
  • Ohlei, Olena
  • Bos, Isabelle|||0000-0001-9648-6428
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Prokopenko, Dmitry|||0000-0002-1844-5652
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Andreasson, Ulf
  • Blennow, Kaj|||0000-0002-1890-4193
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Gabel, Silvy
  • Scheltens, Philip|||0000-0002-1046-6408
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Blin, Olivier
  • Richardson, Jill|||0000-0001-6564-3187
  • Bordet, Régis|||0000-0003-3916-6422
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Popp, Julius|||0000-0002-0068-0312
  • Clark, Christopher|||0000-0001-7210-7702
  • Peyratout, Gwendoline
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Tainta, Mikel|||0000-0003-0624-1211
  • Peyratout, J.B.
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Tanzi, Rudolph E.|||0000-0002-7032-1454
  • ten Kate, Mara|||0000-0002-8290-8543
  • Wittig, Michael
  • Franke, Andre|||0000-0003-1530-5811
  • Lill, Christina|||0000-0002-2805-1307
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Lovestone, Simon|||0000-0003-0473-4565
  • Streffer, Johannes Rolf|||0000-0002-9387-5951
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Bertram, Lars|||0000-0002-0108-124X
Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively. Methods: We performed genome-wide association studies (GWAS) using DNA and cerebrospinal fluid (CSF) samples from the EMIF-AD Multimodal Biomarker Discovery study for discovery, and the Alzheimer's Disease Neuroimaging Initiative study for validation analyses. GWAS were performed for all three CSF biomarkers using linear regression models adjusting for relevant covariates. Results: We identify novel genome-wide significant associations between DNA variants in TMEM106B and CSF levels of NfL, and between CPOX and YKL-40. We confirm previous work suggesting that YKL-40 levels are associated with DNA variants in CHI3L1. Discussion: Our study provides important new insights into the genetic architecture underlying interindividual variation in three AD-related CSF biomarkers. In particular, our data shed light on the sequence of events regarding the initiation and progression of neuropathological processes relevant in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset

  • Homann, Jan
  • Osburg, Tim
  • Ohlei, Olena
  • Dobricic, Valerija|||0000-0001-8559-1097
  • Deecke, Laura
  • Bos, Isabelle|||0000-0001-9648-6428
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Gabel, Silvy
  • Scheltens, Philip|||0000-0002-1046-6408
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Blin, Olivier
  • Richardson, Jill|||0000-0001-6564-3187
  • Bordet, Régis|||0000-0003-3916-6422
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Popp, Julius|||0000-0002-0068-0312
  • Clark, Christopher|||0000-0001-7210-7702
  • Peyratout, Gwendoline
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Tainta, Mikel|||0000-0003-0624-1211
  • Dobson, Richard James Butler|||0000-0003-4224-9245
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Wittig, Michael
  • Franke, Andre|||0000-0003-1530-5811
  • Lill, Christina|||0000-0002-2805-1307
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lovestone, Simon|||0000-0003-0473-4565
  • Streffer, Johannes Rolf|||0000-0002-9387-5951
  • ten Kate, Mara|||0000-0002-8290-8543
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Bertram, Lars|||0000-0002-0108-124X
Alzheimer's disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, aging populations. AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade. Most of these GWAS used dichotomized clinical diagnostic status, i.e., case vs. control classification, as outcome phenotypes, without the use of biomarkers. An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work. Specifically, we utilized genotype and phenotype data from n = 931 individuals collected under the auspices of the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study to perform a total of 19 separate GWAS analyses. As outcomes we used five magnetic resonance imaging (MRI) traits and seven cognitive performance traits. For the latter, longitudinal data from at least two timepoints were available in addition to cross-sectional assessments at baseline. Our GWAS analyses revealed several genome-wide significant associations for the neuropsychological performance measures, in particular those assayed longitudinally. Among the most noteworthy signals were associations in or near EHBP1 (EH domain binding protein 1; on chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall as well as SMOC2 (SPARC related modular calcium binding 2; 6p27) with immediate recall in a memory performance test. On the X chromosome, which is often excluded in other GWAS, we identified a genome-wide significant signal near IL1RAPL1 (interleukin 1 receptor accessory protein like 1; Xp21.3). While polygenic score (PGS) analyses showed the expected strong associations with SNPs highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not show noteworthy associations with recent AD risk GWAS findings. In summary, our study highlights the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and nominates several new loci not previously implicated in cognitive decline.